List price stays high, and cash-pay patients feel it most
Importantly, current therapeutic approaches focus on alleviating immune-mediated injury to the kidney, mainly targeting the migratory and functional features of immune cells with little impact on fibrosis or chronicity
Tuersun, A., Mohetaer, M., Hou, G
Treatment Discontinuation Data shows 16.6% of semaglutide patients stopped treatment[link_2] due to side effects, versus 8.2% in the placebo group
GLP-1 Receptor Agonist Top Companies and Strategic Involvements The global GLP-1 receptor agonist market size is calculated at USD 53.5 billion in 2024, grew to USD 62.86 billion in 2025, and is projected to reach around USD 268.37 billion by 2034
From Hurricane to Washington City people work hard to lose weight but often feel like theyre fighting their own bodies